RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.
He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.
The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.
RedHill Biopharma Ltd. director Mamluk Roni has filed an initial ownership report detailing existing equity awards and share holdings. The filing shows 10,350 unvested restricted share units, each tied to one American Depositary Share (ADS). Each ADS represents 10,000 ordinary shares of RedHill Biopharma Ltd.
The RSUs are subject to time-based vesting conditions and are settled in ordinary shares. The report also discloses 1,350 ADSs that are convertible at any time at the holder’s election and have no expiration date. This Form 3 does not reflect new buy or sell transactions, only current beneficial ownership.
RedHill Biopharma Ltd. Chief Financial Officer Ingber Razi filed a Form 3 reporting existing equity interests in the company, rather than new open‑market trades. The filing lists American Depositary Shares (ADSs), restricted share units (RSUs) and stock options tied to Ordinary Shares.
The holdings include 27,756 unvested RSUs, each for one ADS, with each ADS representing 10,000 Ordinary Shares of par value NIS 0.01. The filing also notes 6,691 ADSs that are convertible at any time with no expiration date, plus fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares at fixed exercise prices per ADS, expiring between August 29, 2028 and April 28, 2031.
RedHill Biopharma Ltd. executive Guy Joel Goldberg filed a Form 3 reporting his initial ownership in the company. He directly holds American Depositary Shares and Ordinary Shares, including 30,572 unvested restricted share units, each tied to one ADS that represents 10,000 Ordinary Shares. He also holds fully vested stock options to purchase 250,000, 450,000, 370,000 and 600,000 Ordinary Shares at exercise prices of $5,000, $4,870, $5,000 and $7,080 per ADS, expiring between 2028 and 2031.
RedHill Biopharma executive Adi Frish filed an initial ownership report showing existing equity interests, not new trades. He reports 27,681 unvested restricted share units tied to American Depositary Shares, 6,280 ADSs that are convertible at any time, stock options over 250,000, 370,000, 600,000 and 750,000 ordinary shares, and 276,810,000 ordinary shares held directly.
RedHill Biopharma Ltd. director Cabilly Shmuel has filed an initial ownership report detailing a substantial equity stake in the company. He directly holds 105,200,000 Ordinary Shares, along with American Depositary Shares, restricted share units and stock options linked to additional Ordinary Shares.
The holdings include 10,520 unvested restricted share units, each tied to one American Depositary Share (ADS) that represents 10,000 Ordinary Shares, and 3,063 ADSs that are convertible at any time at the holder’s election and have no expiration date. He also holds fully vested stock options to purchase 90,000 Ordinary Shares at an exercise price of $4,870 per ADS expiring on March 25, 2030, and options to purchase 180,000 Ordinary Shares at an exercise price of $7,080 per ADS expiring on April 28, 2031.
RedHill Biopharma Ltd. director and Chief Executive Officer Dror Ben-Asher filed an initial ownership report showing substantial equity and option interests in the company. He directly holds 441,350,000 Ordinary Shares and 10,336 American Depositary Shares (ADSs)
The filing also discloses 44,135 unvested restricted share units (RSUs)750,000, 500,000, 900,000, and 1,100,000 Ordinary Shares at exercise prices of $5,000, $5,000, $4,870, and $7,080 per ADS, expiring between 2028 and 2031.
RedHill Biopharma Ltd. reported that at its Extraordinary General Meeting of Shareholders held on March 5, 2026, all resolutions proposed to shareholders were duly approved. The company also states that this report is incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements previously filed with the U.S. securities regulator.
RedHill Biopharma reports that full U.S. sales and operational launch of Talicia has begun under a joint commercialization agreement with Cumberland Pharmaceuticals. The launch is managed by Talicia Holdings Inc. (THI), a jointly controlled operating entity owned 70% by RedHill and 30% by Cumberland.
This operational start follows a previously announced joint commercialization model that included Cumberland’s $4 million strategic investment. The partners aim to accelerate Talicia’s market penetration and reach by integrating commercial resources and coordinating promotion activities.
Talicia is the only FDA‑approved all‑in‑one, low‑dose rifabutin‑based therapy for H. pylori infection and is listed as an empiric first‑line treatment option in the 2024 American College of Gastroenterology guideline. H. pylori affects about 35% of U.S. adults, with an estimated 1.6 million patients treated annually, making this a large target market. RedHill is also pursuing Talicia approvals and licensing opportunities in additional territories, including the UK, the Middle East, and other ex‑U.S. markets.